Analysis of reported adverse drug reactions registered in Mongolia (2020-2025)
- VernacularTitle:Монгол улсад бүртгэгдсэн эмийн гаж нөлөөний мэдээлэлд хийсэн дүн шинжилгээ (2020–2025)
- Author:
Enkhlen Narmandakh
1
;
Byambasuren Gerelt-Od
1
;
Ulambayar Lkhamsuren
1
Author Information
1. Department of Pharmaceutical Management and Organization, Mongolian University of Pharmaceutical Sciences, Ulaanbaatar, Mongolia
- Publication Type:Journal Article
- Keywords:
adverse drug reaction;
pharmacovigilance;
drug safety;
Mongolia
- From:
Mongolian Pharmacy and Pharmacology
2026;29(2):48-54
- CountryMongolia
- Language:Mongolian
-
Abstract:
Introduction:Systematic analysis of adverse drug reactions (ADRs) is essential for enhancing drug
safety policies in Mongolia. This study analyzed ADR patterns and reporting trends between 2020
and 2025.
Methods:This study employed a retrospective cross-sectional design using ADR reports recorded
between 2020 and 2025. The dataset included variables such as drug name, drug classification,
clinical manifestations of ADRs, and affected organ systems. Data were entered into Microsoft
Excel and analyzed using SPSS version 25. Drugs were classified according to the World Health
Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system, and ADRs were
analyzed at the organ system level.
Conclusion:Analysis of 634 reported adverse drug reactions (ADRs) in Mongolia from 2020 to 2025
showed that antibiotics, particularly third-generation cephalosporins, accounted for the majority of
ADRs. According to Hartwig’s severity assessment, 70–80% of ADRs were mild, 15–20% moderate,
and 5% severe, indicating that while most reactions did not require intervention, a small proportion
could be lifethreatening. These findings highlight the need to strengthen pharmacovigilance systems,
improve ADR reporting, and enhance the quality of data in Mongolia.
- Full text:2026080201592555321MPPJ-2026-29(2)-48-54.pdf
